373 related articles for article (PubMed ID: 16683212)
1. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
[TBL] [Abstract][Full Text] [Related]
2. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
[TBL] [Abstract][Full Text] [Related]
3. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
4. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
5. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.
Cho JS; Her SH; Baek JY; Park MW; Kim HD; Jeong MH; Ahn Yk; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae JK; Rhew JY; Chae IH; Cho MC; Bae JH; Rha SW; Kim CJ; Choi D; Jang YS; Yoon J; Chung WS; Cho JG; Seung KB; Park SJ;
J Korean Med Sci; 2010 Nov; 25(11):1601-8. PubMed ID: 21060749
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors.
Kovar D; Canto JG; Rogers WJ
Am J Cardiol; 2002 Nov; 90(9):911-5. PubMed ID: 12398953
[TBL] [Abstract][Full Text] [Related]
10. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Mehta RH; Roe MT; Chen AY; Lytle BL; Pollack CV; Brindis RG; Smith SC; Harrington RA; Fintel D; Fraulo ES; Califf RM; Gibler WB; Ohman EM; Peterson ED
Arch Intern Med; 2006 Oct; 166(18):2027-34. PubMed ID: 17030838
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of anticoagulation in acute coronary syndromes.
Latour-Pérez J; de-Miguel-Balsa E
Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
13. Managing acute coronary syndrome: evidence-based approaches.
Spinler SA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441
[TBL] [Abstract][Full Text] [Related]
14. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.
Hoekstra JW; Roe MT; Peterson ED; Menon V; Mulgund J; Pollack CV; Miller C; Palabrica T; Harrington RA; Ohman EM; Gibler WB
Acad Emerg Med; 2005 May; 12(5):431-8. PubMed ID: 15863399
[TBL] [Abstract][Full Text] [Related]
15. Influence of clinical trial participation on subsequent antithrombin use.
Shah BR; Peterson ED; Chen AY; Mahaffey KW; DeLong ER; Ohman EM; Pollack CV; Gibler WB; Roe MT
Clin Cardiol; 2010 Mar; 33(3):E49-55. PubMed ID: 20127904
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
18. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
19. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
